It's more than a result.
It's a person.

We're Driven To Know.


Innovative solutions that empower researchers, from ALS to fragile X syndrome.

Learn more about our Genetics portfolio

Solving complex molecular challenges, from leukemia to solid tumors.

Learn more about our Oncology portfolio
Custom & Companion Diagnostics

One partner from clinical concept to product commercialization.

Learn more about partnering with us.

FDA Grants Premarket Clearance of Asuragen’s AmplideX® Fragile X Dx and Carrier Screen Kit

Our AmplideX® Fragile X Dx and Carrier Screen Kit has been cleared by the United States Food and Drug Administration (FDA), making it the first and only test for the detection and quantification of expanded pathogenic repeat sequences to be cleared by the FDA.

Learn More

Asuragen Announces Launch of AmplideX® PCR/CE SMN1/2 Plus Kit

The AmplideX® PCR/CE SMN1/2 Plus Kit is a clinical research tool providing the most comprehensive analysis of SMN1 and SMN2 currently available from a commercial kit.

Learn more

Asuragen Expands Genetic Portfolio with Launch of AmplideX® PCR/CE HTT Kit

The AmplideX® PCR/CE HTT Kit is a simple, robust, and reliable test for the detection of CAG trinucleotide repeats within the HTT gene, aberrations which are associated with the development of Huntington’s Disease (HD).

Read more

The Latest from Asuragen

From Two Days to Four Hours: How the AmplideX® PCR/CE SMN1/2 Plus Kit Provides SMN1 and SMN2 Copy Number Information and More…
Back To

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.